China Is Considering Combining COVID-19 Vaccines To Increase Protection
Published On:April 14, 2021
China's top disease control official has stated that the country is considering combining COVID-19 vaccines in order to improve vaccine efficacy. Chinese vaccines, according to available data, lag behind others in terms of effectiveness, including Pfizer and Moderna, but need less strict temperature controls during storage.
According to data from a Phase III trial in Brazil, two injections of a vaccine produced by China's Sinovac Biotech were 49.1% successful when delivered less than three weeks apart, falling short of the World Health Organization's 50% threshold, according to a paper published by Brazilian researchers on Sunday ahead of peer review.
However, data from a small subgroup revealed that when doses were administered at three-week intervals or longer, the efficacy rate increased to 62.3 percent. In the study, the vaccine's overall efficacy rate was marginally higher than 50%. China has produced four domestic vaccines that have been licenced for public use and a fifth that will be used on a smaller scale in the event of an emergency. On Saturday, a government official predicted that the country will generate 3 billion doses by the end of the year.
Sinopharm, a Chinese pharmaceutical company, has not published any comprehensive efficacy data on its vaccines. Based on preliminary results, it claims that two vaccines produced by its units are 79.4 percent and 72.5 percent successful, respectively. Both vaccine manufacturers have provided data on their COVID-19 vaccines that show efficacy levels that meet WHO requirements, according to a WHO panel in March. China has exported millions of vaccines, and officials and state media have defended the vaccines vehemently while questioning the safety and logistics of other vaccines.
Are you looking for a Market Research Reports? Just contact our consultant.